

LEARN ABOUT THE PROJECT:





Title of the project:

"Computational biomechanics and bioengineering 3D printing to develop a personalized regenerative biological ventricular assist device to provide lasting functional support to damaged hearts"





BRAVE combines cell reprogramming, biomaterials, and 3D printing with myocardial physiology insights. By engineering regenerative tissues using stem cells and advanced computational models, BRAV3 seeks to enhance heart development knowledge and push novel medical technologies towards clinical application.















Main Expected Results:

Key results include engineering human-sized cardiac tissue that mimics myocardial properties, using hiPSC technology to create aligned, vascularized cardiac cells, and maturing these constructs in specialized bioreactors.

Through preclinical trials in porcine models, BRAV3 will validate BioVAD's safety and efficacy as a one-time regenerative treatment for ischemic heart disease. This work is anticipated to reduce healthcare burdens, enhance patient outcomes, and advance the EU's leadership in regenerative medicine and bioengineering.







This project is funded by European Union's Horizon 2020 research and innovation programme under grant agreement 874827









- Start date: 2020.01.01
- **End date:** 2025.06.30 (extended)
- Duration: 60 months



16 partners

Coordinated by

Universidad de Navarra

6 countries

























UMC Utrecht




















Role of PNO Portugal:

Leaders of Exploitation and Commercialisation activities



Follow the project!



www.projectbrave.eu



@brav3_eu





Contact person in PNO Portugal



Mariana Cerqueira, PhD



Innovation consultant



mariana.cerqueira@pnoconsultants.com

